

Better access to R&D

Workshop #3 Innovation & repositionning

Pr Florence GHRENASSIA, Pharm D., MBA Director Office of Tech Transfer AP-HP

June 24, 2015 – Museum of Fine arts, Nancy, France

Value chain

From academic research



©Next Gen African Farmers

esearch / Healthcare **Patients**

Health care employees, nurses

Physicians, biologists, pharmacist


- Patients comfort optimization
- Modification of medical devices
- Innovative Rehabilitation tools
- Innovative logistic or technical



- Orphan uses, antidotes
- Cell & gene therapy
- Compounding pharmacy, specials
- Galenic innovation, Dose optimization
- Registers Cohorts
- Data's bases, tumor banks
- Biological collections, banks
- Expertise, networks

- Diagnostic tests
- Biomarkers, genetic markers
- Targets identification
- Leads optimization

Patents



Repositionning Strategy to new markets




Pharma (Compounds & Vaccines)

Diagnostic

Medical device

Acide cholique C24H40O5

 1992: Pr Jacquemin treated with Ac Cholique patients with rare disease



- Deficit in hepatic enzyms (3beta-HSD & delta4-3 oxo-R)
- 1993: Clinical trial sponsored by AP-HP with Ac Cholic prepared by Bicêtre pharmacy
- 1997: Success of the treatment in 1 to 8 monthes

 Jacquemin E, Hermans E, Myara A, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997; 25:519-23
- 2002: Orphan Designation EMA by AP-HP (AGEPS)
- 2007: Partnership with CTRS
 Clinical datas transfer and designation
- 2013: Europe approval (European Medicine Agency)
- 2014: ASMR 1, ANSM, Galien Prize, Golden Pill

Iron

- 3000 years ago, first therapeutic preparation based on iron
- Melampus cured the son of Argos king by making him drink a potion which had been plunged into his sword intent that it files its rust
- XVI century, Iron treatments used as purgatives, emetics, cauteries legs or bleeds
- 1713, Louis Lemery & Etienne Francois Geoffroy discovered that iron is a component of blood
- 1975, First specialty injectable iron (FER LUCIEN®, IM)
- 2004, Iron patented for ADHD

Ceramic for medical and optic use

Chemical neutrality

Composition from those of neighboring bone tissue

Biological tolerance by the body

Torsional strength

Resistance to friction

Optical Properties

Hardness

Eye Surgery

Dental implants / Protheses

Bone prostheses / substitute

Orthondontie (barckets)

Surgical tools and Instrumentation

Medical instruments and analysis

Medical implants (Cochlear, pacemakers)

Lasers

Infrared detectors

Application examples

Concrete, plaster, brick for medical use

- Development of a radiology facility
- Protection of walls of the room
- Ensure the protection of workers and the public
- Depends on the delimitation of controlled and supervised areas compared to adjoining areas

Serendipity

Learning { Insights, Experiences, Relationships, Networks }

Behavior { Curiosity, Commitment, Divergence, Generocity }

+ Stimulation { Events, Collisions, Reflection, Recombination Recombination }

Conditions for Serendipity

© Colin Raney

Bupropion, C13H18CINO

- 1997, patented as a drug for depression (Wellbutrin)
- Several observations: depressed patients under bupropion stopped smoking
- Investigation showed that bupropion reduces the need for nicotine by acting on dopamine
- 2002, bupropion was patented (Zyban new name) as a treatment to stop smoking

Sildenafil C22H30N6O4S

- 1996: Patented by Pfizer
 Dedicated to angora treatment (Cardiac disease)
- 1997: First clinical trial shows no effect on angor but serious side effects on erection
- 1998: US approval for drug on dyserectile troubles (FDA)
- 1999: Europe approval (EMA)
- 2011: Generic drugs arrival

Know how, ultimate weapon

Know how regulation?

CEE n°4087/88 du 30/11/88 & CE n°2790/1999 22/12/99 (Rglt UE n°316/2014 23/03/14)


Practical information, resulting from experience and tested

- Secret: it is not generally known or easily accessible
- Substantial: significant and useful for the production of contract products (commercial value)
- **Identified**: described in a sufficiently complete manner to allow verification that it meets the conditions secret

Murano (Venise, Italy)



Saint Gobain, France



@ Les Echos



- (19) United States
- (12) Patent Application Publication (10) Pub. No.: US 2015/0160400 A1 Massault et al.
 - Jun. 11, 2015 (43) Pub. Date:
- (54) ILLUMINATING GLAZING WITH INCORPORATED DEFLECTOR
- (71) Applicant: SAINT-GOBAIN GLASS FRANCE. Courbevoie (FR)
- (72) Inventors: Laetitia Massault, Magny Les Compiegne (FR); Pascal Bauerle, Roye (FR); Christophe Kleo, Attichy (FR); Adéle Verrat-De-Bailleul, Villers-sur-Coudun (FR); Mathieu Berard, Paris (FR); Brice Dubost, Courbevoie (FR)
- (73) Assignee: SAINT-GOBAIN GLASS FRANCE, Courbevoie (FR)
- (21) Appl. No.: 14/399,826
- (22) PCT Filed: May 3, 2013
- (86) PCT No.: PCT/FR2013/050990 § 371 (c)(1), (2) Date: Nov. 7, 2014

Foreign Application Priority Data

May 10, 2012 (FR) 1254297


Publication Classification

(51) Int. Cl. F21V 8/00 (2006.01)B60Q 3/00 (2006.01) B60Q 3/02 (2006.01)


(52) U.S. Cl. G02B 6/0038 (2013.01); G02B 6/0073 (2013.01); B60Q 3/0203 (2013.01); B60Q 3/004 (2013.01)

ABSTRACT

A lighting glazing includes a first sheet of glass of refractive index n1 with a first main face, a second main face and a rim; a transparent polymer film in adhesive contact with the second main face of the first sheet, the film having a refractive index n2<n1; a light source positioned facing the rim of the first sheet of glass, wherein an area of the second main face of the first sheet of glass is provided with a reflecting relief or else is covered with a transparent flat structure, of refractive index n3 greater than or equal to n1, provided with a reflecting



@ Romania News



Disadvantages Secret / Patent

Disadvantages Protection by Secret

- Difficulty and cost maintain secrecy
- Disclosure by others
- No exclusive right operating
- Limited Legal protection
- Random Life

Disadvantages Protection by Patent

- Cost and quality if strategy random
- Disclosure
- Access to the third 18 months the filing of the application patent

Benefits Secret / Patent

Benefits of protection secret

- No limitation in time, except for disclosure
- No limitation geographical
- No court fees
- No criterion patentability
- Immediate effect

Benefits of protection patent

- 20 years of exclusivity
- Power to International development
- Competitive & heritage Advantage
- Source of income by structuring Agreements partnership
- Visibility

Business models



Pharmacy

B to B

B to C

Diagnostic


Plateforms

Point of care

Med tech

Hospital centred

Patient centred




From a passive and **limited data** collection

...to a continue monitoring patient centred

© Withings


Open up barriers



Building bridges and breaking barriers

- Working with a broad spectrum of industries
- Combined with a wide academic network
- Opportunity to bring knowledge from one industry or application to another.
- Knowledge transfer
- Open up for new innovations
- More innovative product development.

Crossing skills to innovate



lorence.ghrenassia@aphp.fr
@valorisation

Thank you!